<DOC>
	<DOCNO>NCT02067793</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety NRX-1074 follow single intravenous dose subject major depressive disorder .</brief_summary>
	<brief_title>Study Intravenous NRX-1074 Patients With Major Depressive Disorder</brief_title>
	<detailed_description>NRX-1074 N-methyl-D-aspartate ( NMDA ) receptor functional partial agonist efficacy animal model affective disorder include major depressive disorder . The purpose study evaluate efficacy safety NRX-1074 dose level predict comparison human animal pharmacokinetics efficacious .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Male female subject Aged 18 65 year Meets Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSMIVTR ) criteria major depressive disorder ( MDD ) Current episode last ≥ 8 week Screening HDRS17 score ≥ 21 begin washout current antidepressant agent and/or adjuvant agent HDRS17 score ≥ 21 Baseline ( 14 day washout current antidepressant agent ) Female subject childbearing potential negative serum pregnancy test prior entry study practice adequate method birth control ( eg oral parenteral contraceptive , intrauterine device , barrier , abstinence ) plan become pregnant course study . Female subject may include without negative serum pregnancy test surgically sterile least 2 year postmenopausal Male subject female sexual partner use acceptable method birth control study Clinical laboratory value &lt; 2 time upper limit normal ( ULN ) deem clinically significant per investigator Naurex medical monitor Ability understand requirement study , provide write informed consent , abide study restriction , agree return require assessment Based investigator Naurex medical monitor 's clinical judgment , subject eat disorder , obsessive compulsive disorder ( OCD ) , panic disorder , posttraumatic stress disorder ( PTSD ) , generalize anxiety disorder secondary major depressive episode permit Axis I diagnosis delirium , dementia , dysthymia , amnestic cognitive disorder , schizophrenia psychotic disorder , bipolar I II disorder , eat disorder ( anorexia bulimia nervosa ) , obsessivecompulsive disorder , panic disorder , agoraphobia , social phobia , attentiondeficit hyperactivity disorder ( ADHD ) , PTSD A clinically significant current Axis II diagnosis borderline , antisocial , paranoid , schizoid , schizotypal , histrionic personality disorder Experiencing hallucination , delusion , psychotic symptomatology current episode ; lifetime history psychosis Huntington 's , Parkinson 's , Alzheimer 's , Multiple Sclerosis , history seizure stroke Currently hospitalize reside inpatient facility study participation Substance abuse within last 12 month , include great equal 5 unit alcohol per day 1 unit = 1/2 pint beer , 1 glass wine , 1 oz . spirit consume week opinion investigator Allergy intolerance current antidepressant current medication Participation clinical trial investigational product device within 30 day enrollment trial Positive screen drug abuse : cocaine , marijuana , PCP , ketamine , opioid agent opinion investigator abuse Have receive electroconvulsive therapy , transcranial magnetic stimulation ( TMS ) , vagal nerve stimulation ( VNS ) current depressive episode Post current ( past 6 month ) suicide risk base administration CSSRS investigator 's clinical judgment Human immunodeficiency virus ( HIV ) infection ( base HIV1 &amp; HIV2 antibody screen ) ongoing infectious disease Females female partner male subject currently pregnant plan become pregnant course study . Women breastfeed Currently take prescription ( psychiatric treatment , antidepressant treatment ) overthecounter medication include herbal therapy treat MDD condition secondary period follow study drug dosing . Dextromethorphan tramadol since serotonin uptake inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>NRX-1074</keyword>
	<keyword>NMDA Receptor Modulator</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Glycine site modulator</keyword>
</DOC>